Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Chromadex Corp CS (CDXC)

Chromadex Corp CS (CDXC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 209,873
  • Shares Outstanding, K 55,522
  • Annual Sales, $ 31,560 K
  • Annual Income, $ -33,320 K
  • 60-Month Beta 1.16
  • Price/Sales 6.53
  • Price/Cash Flow N/A
  • Price/Book 9.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.10
  • Low Estimate -0.13
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +20.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.70 +6.51%
on 06/24/19
4.61 -14.52%
on 05/28/19
-0.65 (-14.14%)
since 05/24/19
3-Month
3.70 +6.51%
on 06/24/19
4.95 -20.39%
on 05/10/19
-0.03 (-0.74%)
since 03/26/19
52-Week
2.79 +41.25%
on 12/11/18
5.00 -21.18%
on 08/09/18
+0.11 (+2.89%)
since 06/26/18

Most Recent Stories

More News
TRU NIAGEN(R) Awarded 'Ingredient of the Year: Healthy Aging' by NutraIngredients-USA

ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship consumer product, Tru Niagen(R) (nicotinamide riboside) received the 'Ingredient of the Year: Healthy Aging' award at the NutraIngredients-USA...

CDXC : 3.86 (+2.12%)
ChromaDex to Present at the 20th Annual B. Riley FBR Investor Conference

ChromaDex Corp. (NASDAQ:CDXC) announced today that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will present at the 20 Annual B. Riley FBR Investor Conference at the...

CDXC : 3.86 (+2.12%)
ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

ChromaDex (CDXC) delivered earnings and revenue surprises of 0.00% and 2.58%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CDXC : 3.86 (+2.12%)
ChromaDex Corporation Reports First Quarter 2019 Financial Results

- First Quarter 2019 Net Revenues Increased by 53% to $10.0 Million -

CDXC : 3.86 (+2.12%)
ChromaDex Announces $10 Million Issuance of Convertible Notes

ChromaDex Corp. (NASDAQ:CDXC) announced today that it has entered into a note purchase agreement for the sale of $10.0 million of convertible notes in a private placement. The transaction was led by international...

CDXC : 3.86 (+2.12%)
ChromaDex to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Thurs., May 9, 2019 at 4:30 p.m. Eastern time to discuss its financial results for the first quarter ended March 31, 2019....

CDXC : 3.86 (+2.12%)
ChromaDex Furthers TRU NIAGEN(R) Global Expansion in Canada with WELL Health Technologies

ChromaDex Corp. (NASDAQ:CDXC) announced today a new distribution partnership for TRU NIAGEN(R) with Vancouver-based WELL Health Technologies Corp. (TSX.V: WELL) who intends on distributing TRU NIAGEN(R)...

CDXC : 3.86 (+2.12%)
WELL.VN : 0.910 (+1.11%)
ChromaDex Drives Global Expansion Strategy for TRU NIAGEN(R) with Specialty Retail Launch and Expanded eCommerce Distribution in Canada

ChromaDex Corp. (NASDAQ:CDXC) announced today the latest milestone in its global expansion strategy for TRU NIAGEN, with a strategic deal with specialty retailer Showcase in Toronto, Canada. Tru Niagen...

CDXC : 3.86 (+2.12%)
New Study Deepens Research Into the Potential Cardiovascular Health Benefits of Supplementation with Nicotinamide Riboside (NR)

ChromaDex Corp. (NASDAQ:CDXC) today reported that results of a new preclinical study showed that supplementation with the unique B3 vitamin nicotinamide riboside (NR, or Niagen(R))...

CDXC : 3.86 (+2.12%)
Dr. Charles Brenner, Discoverer of Nutrient Nicotinamide Riboside as a Vitamin, Announced as Speaker at Upgrade XP's Sixth Annual Biohacking Conference

ChromaDex Corp. (NASDAQ:CDXC) announced today its Chief Scientific Advisor, Dr. Charles Brenner, the world's foremost authority on NAD metabolism and discoverer of nicotinamide riboside as a vitamin, will...

CDXC : 3.86 (+2.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CDXC with:

Business Summary

ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is...

See More

Key Turning Points

2nd Resistance Point 3.91
1st Resistance Point 3.85
Last Price 3.86
1st Support Level 3.71
2nd Support Level 3.64

See More

52-Week High 5.00
Fibonacci 61.8% 4.16
Fibonacci 50% 3.89
Last Price 3.86
Fibonacci 38.2% 3.63
52-Week Low 2.79

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar